Literature DB >> 11472406

Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols.

T Yoshida1, K Okuda, K Q Xin, K Tadokoro, J Fukushima, S Toda, E Hagiwara, K Hamajima, T Koshino, T Saito.   

Abstract

We constructed a recombinant replication defective adenovirus vector containing the env gene (Ad-Bal) derived from macrophage-trophic HIV-1 (HIV-1 Bal). We then immunized mice with this vector using several administration routes and protocols, and examined the immune response. When the Ad-Bal viral vector (over 1 x 10(7) pfu) was injected subcutaneously, both humoral and cell-mediated immunities were induced. However, immune response induced by the Ad-Bal vector alone was weaker than that induced by the recombinant vaccinia viral vector. We then employed the following three immunization protocols: (l) DNA vaccination followed by immunization with the Ad-Bal; (2) vaccination using the Ad-Bal vector followed by DNA vaccination; and (3) DNA vaccination followed by Ad-Bal infection and passive transfer of dendritic cells (DCs) infected with the Ad-Bal. Among the three protocols, the last gave the strongest humoral and cell-mediated immunity. These results suggest that the combination of DNA vaccination, Ad-Bal vector infection and passive transfer of Ad-Bal-infected DCs can induce strong immunity against HIV-1 Bal.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11472406      PMCID: PMC1906078          DOI: 10.1046/j.1365-2249.2001.01540.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  50 in total

1.  Immunization against AIDS in humans.

Authors:  D Zagury; R Léonard; M Fouchard; B Réveil; J Bernard; D Ittelé; A Cattan; L Zirimwabagabo; M Kalumbu; W Justin
Journal:  Nature       Date:  1987 Mar 19-25       Impact factor: 49.962

2.  Trans-activation of the human immunodeficiency virus long terminal repeat sequences, expressed in an adenovirus vector, by the adenovirus E1A 13S protein.

Authors:  A P Rice; M B Mathews
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

3.  Production of human immunodeficiency virus (HIV)-like particles from cells infected with recombinant vaccinia viruses carrying the gag gene of HIV.

Authors:  T Shioda; H Shibuta
Journal:  Virology       Date:  1990-03       Impact factor: 3.616

4.  A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals.

Authors:  M Larsson; X Jin; B Ramratnam; G S Ogg; J Engelmayer; M A Demoitie; A J McMichael; W I Cox; R M Steinman; D Nixon; N Bhardwaj
Journal:  AIDS       Date:  1999-05-07       Impact factor: 4.177

5.  Genetic control of immune response to sperm whale myoglobin in mice. II. T lymphocyte proliferative response to the synthetic antigenic sites.

Authors:  K Okuda; S S Twining; C S David; M Z Atassi
Journal:  J Immunol       Date:  1979-07       Impact factor: 5.422

6.  Isolation of deletion and substitution mutants of adenovirus type 5.

Authors:  N Jones; T Shenk
Journal:  Cell       Date:  1978-01       Impact factor: 41.582

7.  Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.

Authors:  T Tüting; J Steitz; J Brück; A Gambotto; K Steinbrink; A B DeLeo; P Robbins; J Knop; A H Enk
Journal:  J Gene Med       Date:  1999 Nov-Dec       Impact factor: 4.565

8.  Rescue of Sendai virus from viral ribonucleoprotein-transfected cells by infection with recombinant vaccinia viruses carrying Sendai virus L and P/C genes.

Authors:  H Gotoh; T Shioda; Y Sakai; K Mizumoto; H Shibuta
Journal:  Virology       Date:  1989-08       Impact factor: 3.616

9.  Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism.

Authors:  B R Cullen
Journal:  Cell       Date:  1986-09-26       Impact factor: 41.582

10.  A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS.

Authors:  D Zagury; J Bernard; R Cheynier; I Desportes; R Leonard; M Fouchard; B Reveil; D Ittele; Z Lurhuma; K Mbayo
Journal:  Nature       Date:  1988-04-21       Impact factor: 49.962

View more
  4 in total

1.  An adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent deltaE1-E2-E3-E4 Ad5 vectors.

Authors:  Daniele Catalucci; Elisabetta Sporeno; Agostino Cirillo; Gennaro Ciliberto; Alfredo Nicosia; Stefano Colloca
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

2.  Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.

Authors:  Jun Zhao; Joel Pinczewski; Victor R Gómez-Román; David Venzon; V S Kalyanaraman; Phillip D Markham; Kristine Aldrich; Matthew Moake; David C Montefiori; Yuanmei Lou; George N Pavlakis; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

3.  Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120.

Authors:  L Jean Patterson; Nina Malkevitch; Joel Pinczewski; David Venzon; Yuanmei Lou; Bo Peng; Cindy Munch; Melissa Leonard; Ersell Richardson; Kristine Aldrich; V S Kalyanaraman; George N Pavlakis; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

Review 4.  Adenoviruses as vaccine vectors.

Authors:  Nia Tatsis; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2004-10       Impact factor: 11.454

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.